by Lauren Amphlett | Apr 15, 2024 | Antifungals in development, General interest, Latest research news
Airway epithelial cells (AECs) are a key component of the human respiratory system: The first line of defence against airborne pathogens such as Aspergillus fumigatus (Af), AECs play a crucial role in initiating host defence and controlling immune responses and are...
by Seren Evans | Mar 22, 2023 | Antifungals in development, General interest, Latest research news
The numbers of people at risk of fungal infections are increasing due to an aging population, increased use of immunosuppressive medications, pre-existing medical conditions, environmental changes, and lifestyle factors. Therefore, there is a growing need for new...
by Seren Evans | Mar 9, 2023 | Antifungals in development, General interest, Latest research news
ABPA (Allergic Bronchopulmonary Aspergillosis) is a serious allergic disease caused by a fungal infection of the airways. People with ABPA usually have severe asthma and frequent flare-ups that often require long-term use of oral steroids and antibiotics to treat...
by Lauren Amphlett | Oct 8, 2021 | Antifungals in development, General interest, Information and Learning, Latest research news
Many of our patients already know of the increasing need for new antifungal drugs; treatments for fungal diseases like aspergillosis have significant limitations. Toxicities, drug-drug interactions, resistance, and dosing are all issues that can complicate therapy;...
by GAtherton | Jan 20, 2020 | Antifungals in development, Information and Learning, Latest research news
A review published recently describes the new antifungals that are in the pipeline that offer hope for the future. The new drugs described in the review have novel mechanisms of action to overcome resistance, and some offer new formulations providing distinct...